Member access

4-Traders Homepage  >  Shares  >  Nyse  >  AbbVie Inc    ABBV   US00287Y1091

ABBVIE INC (ABBV)

78
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/24/2015 02/25/2015 02/26/2015 02/27/2015 03/02/2015 Date
60.87(c) 60.62(c) 60.52(c) 60.5(c) 60.46(c) Last
7 900 656 9 983 859 7 328 227 8 649 102 6 150 884 Volume
+0.50% -0.41% -0.16% -0.03% -0.07% Change
More quotes
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis... 
Sector
Pharmaceuticals
Calendar
03/04 | 10:00amPresentation
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 22 780 M
EBIT 2015 9 160 M
Net income 2015 6 969 M
Debt 2015 4 694 M
Yield 2015 3,39%
Sales 2016 24 782 M
EBIT 2016 10 366 M
Net income 2016 7 731 M
Debt 2016 1 316 M
Yield 2016 3,78%
PER 2015 14,25
PER 2016 12,37
EV / Sales 2015 4,44x
EV / Sales 2016 3,94x
Capitalization 96 366 M
More Financials
Latest news on ABBVIE INC
02/28 INFINITY PHARMACEUTICALS : Offers Company Recaps Full-Year 2014 Financial Result..
02/27 ABBVIE : HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children a..
02/27 ABBVIE : Assigned Patent
02/27 INFINITY PHARMACEUTICALS : Offers Company Update and Issues Full-Year 2014 Finan..
02/26 ABBVIE : Ongoing Research in Neuroscience and Oncology will be Featured at the 2..
02/26 ABBVIE : Launches SigueElGuion.com to Educate Spanish-Speaking Americans about H..
02/26 ENANTA PHARMACEUTICALS : Releases Results Turquoise-I Study
02/25 ABBVIE : Increases Quarterly Dividend
More news
Sector news Biopharmaceuticals
02:21aDJAstraZeneca PLC Acquisition of Rights to Actavis' Portfolio
01:38a SHIRE : *goldman raises shire price target to 6400 pence - 'conviction buy list'
01:36aDJMerck Profit Slips Despite Revenue Gains
Plus d'actualités du secteur Biopharmaceuticals
4-Traders Strategies on ABBVIE INC 
02/13A likely recovery
More Strategies


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF